Compares two imaging agents for detecting prostate cancer on PET scans
Compares a new PET imaging agent with an existing one in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Key facts
- Where
- Hefei, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06756334, who can take part
Where in China
- The First Affiliated Hospital of China University of Science and Technology（Anhui Provincial Hospital）Hefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anhui Provincial Hospital
- Trial code
- NCT06756334
- Record updated
- 3 January 2025
- Original description
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with [18F]F-DCFPyL.Read full original descriptionShow less
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with [18F]F-DCFPyL.
Inclusion: Aged from 18 to 90 years old; Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.); Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment; simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks; Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment; Sign informed consent.
Exclusion: Concurrent malignant tumors; Previous alcohol allergy; Patients who cannot cooperate with the examination; Patients with liver and kidney dysfunction; Other circumstances deemed by the investigator to be inappropriate for trial participation.